Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015

• Main Authors: Hurt, Aeron C., Besselaar, Terry G., Tilmanis, Danielle, Wang, Dayan, Zhang, Wenqing, Meijer, Adam, Daniels, Rod S., Ermetal, Burcu, Fry, Alicia, Gubareva, Larisa, Huang, Weijuan, Lackenby, Angie, Lee, Raphael T.C., Lo, Janice, Maurer-Stroh, Sebastian, Nguyen, Ha T., Pereyaslov, Dmitriy, Rebelo-de-Andrade, Helena, Siqueira, Marilda M., Takashita, Emi, Tashiro, Masato
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2016
• Subjects: Influenza virus; Antiviral resistance
• Online Access: https://hdl.handle.net/10356/83413; http://hdl.handle.net/10220/41410
• Institution: Nanyang Technological University

The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013–14 (1.9%), but similar to the 2012–13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.